Biopharmaceutical companies are seeing a surge in the amount of data generated and made available to identify better targets, better design clinical trials, enable translational science, and better position products in the market.
Data is being generated from two different sources – science-based data from laboratories including genomics and proteomics data, and real world data from Electronic Health Records (EHRs), claims, wearables, surveys conducted by market research, and social media.
“Biopharmaceuticals can derive significant value and competitive advantage by using data in all parts of their value chain,” said Tom Johnstone, Life Sciences Partner, Knowledgent. “The value propositions are clear: faster and better insights.”
Titled, “Big Data Enabling Better Pharmacovigilance”, this white paper begins with examples of big data sources and the benefits of using such data across the value chain. Then, using pharmacovigilance as an example, the paper delves into approaches of using big data and building a synergy between traditional and big data analytics.
To download a complimentary copy of the white paper, visit knowledgent.com.
Knowledgent is an industry information consultancy that helps organizations transform their information into business results through data and analytics innovation. Our expertise seamlessly integrates industry experience, data analyst and scientist capabilities, and data architecture and engineering skills to uncover actionable insights. We have not only the technical knowledge to deliver game-changing solutions at all phases of development, but also the business acumen to evolve data initiatives from ideation to operationalization, ensuring that organizations realize the full value of their information. For more information, visit knowledgent.com.